Endo International offers its products to the. The company was founded in 1997 and is headquartered Dublin, Ireland. The Company develops, manufactures, markets, and distributes pharmaceutical products and generic drugs. All rights reserved 1 Forward Looking Statements Non-GAAP Financial Measures This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. Endo Internationals earnings have been declining at an average annual rate of -31, while the Pharmaceuticals industry saw earnings growing at 14.8 annually. Q3 2021 Earnings Report 2021 Endo International plc or one of its affiliates. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics.
Generic Pharmaceuticals and International Pharmaceuticals. Find Endo Pharmaceuticals Salaries by Job Title. Branded-Specialty & Established Pharmaceuticals, U.S. The firm operates through the following segments: U.S. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. Current multiples based on per-share metrics (such as earnings per share or book value per share) are calculated using the last closing price, while current multiples based on company-level metrics (such as net sales, EBIT or EBITDA) are calculated using the current market cap or EV (Enterprise Value).Endo International Plc operates as a pharmaceutical company. Use the PitchBook Platform to explore the full. Current multiples include: - Historical multiples based on standardized financials for the last completed fiscal period: Last, Last Twelve Months (LTM) - Forward multiples based on consensus estimates for the current fiscal period and next ones: Next Twelve Months (NTM), FY0, FY1. Information on stock, financials, earnings, subsidiaries, investors, and executives for Endo Pharmaceuticals. Put simply, this method multiplies the sales or profits of a business by an industry averaged multiplier to calculate the Market Value of the business. The market valuation is utilized generally as a primary market input, to provide an objective starting point for the valuation. One of the most widely used quantitative methods is the market multiples method. In reality, business valuation is often a combination of these different approaches. Many methods can be used to value a company. The (current) company valuation of Endo International Plc is therefore way below its valuation average over the last five years. The P/Earnings NTM ratio of Endo International Plc is significantly lower than its historical 5-year average: 2.5. Endo International (ENDP) reported Q3 2022 earnings per share (EPS) of -3.07, missing estimates of 0.37 by 927.76. The company valuation of Endo International Plc according to these metrics is way below the market valuation of its sector. The P/Earnings NTM ratio of Endo International Plc is significantly lower than the average of its sector (Pharmaceuticals): 6.39. The company valuation of Endo International Plc according to these metrics is way below the market valuation of its peer group. The P/Earnings NTM ratio of Endo International Plc is significantly lower than the median of its peer group: around 15.00. A company with a high P/Earnings NTM is considered to be overvalued a company with a low P/Earnings NTM is considered to be undervalued. This multiple is used to compare a company's market value with its earnings. P/E relates the current share price with the market expectations in terms of Earnings Per Share. The most common multiple used in the valuation of stocks is the P/Earnings NTM multiple (Price to Earnings).
Market multiple valuation of Endo International Plc ( ENDP | IRL)
0 kommentar(er)
